CFP
RVMD icon

Catalyst Financial Partners’s Revolution Medicines RVMD Stock Holding History

Catalyst Financial Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$510K Buy
+2,725
New +$398K 0.05% 226
2025
Q4 		– Sell
-4,828
Closed -$225K – 338
2025
Q3 		$225K Buy
+4,828
New +$189K 0.03% 289

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Catalyst Financial Partners's RVMD Position: Q2 2026 in Review

Catalyst Financial Partners opened a new position in Revolution Medicines (RVMD) in Q2 2026: 2,725 shares worth $510K. The stake represents 0.05% of the portfolio and ranks #226 among its holdings. This is a return to the name: Catalyst Financial Partners previously reported a position in RVMD as recently as Q3 2025.

Catalyst Financial Partners first reported a position in RVMD in Q3 2025 and has held it in 2 quarters since. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Catalyst Financial Partners held 2,725 shares of Revolution Medicines worth $510K as of Q2 2026.
  • Revolution Medicines was a new Catalyst Financial Partners position in Q2 2026.
  • Revolution Medicines made up 0.05% of Catalyst Financial Partners's portfolio in Q2 2026, its #226 holding.
  • Catalyst Financial Partners first reported a position in Revolution Medicines in Q3 2025 and has held it in 2 quarters since.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Catalyst Financial Partners's 13F filing for Q2 2026, filed 30 Jul 2026.